World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 7 April 2015
Main ID:  NCT01527032
Date of registration: 28/07/2011
Prospective Registration: No
Primary sponsor: FDA Office of Orphan Products Development
Public title: Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
Scientific title: Risk-adapted Therapy for AL Amyloidosis
Date of first enrolment: September 2002
Target sample size:
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT01527032
Study type:  Interventional
Study design:  Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
Contacts
Key inclusion & exclusion criteria
Health Condition(s) or Problem(s) studied
Amyloidosis
Intervention(s)
Drug: melphalan, thalidomide and dexamethasone
Primary Outcome(s)
Secondary Outcome(s)
Secondary ID(s)
2174
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history